Cara Therapeutics | CARA - Betriebsaufwand

Aktienkurs
2.90
Täglich Wechseln
-0.06 -2.03%
Monatlich
-23.28%
Jährlich
-80.27%
Q2 Prognose
2.82




Betriebsaufwand Veränderung Datum
Acadia Pharmaceuticals USD 266.6M 23.72M 2025-12
Alterity Therapeutics Limited AUD 8.67M 893.38K 2025-12
Assertio Holdings USD 105.8M 12.5M 2025-09
Cara Therapeutics USD 5.94M 983K 2025-09
Cassava Sciences USD 13.55M 1.69M 2025-12
Chugai Pharma JPY 177.3B 604M 2025-12
Cipla INR 60.98B 1.06B 2025-12
Clal Biotechnology ILS 5.15M 9.47M 2022-12
Compugen USD 11.29M 1.51M 2025-12
CSL USD 5.7B 2.82B 2025-12
Grifols EUR 1.99B 217.4M 2025-12
Halozyme Therapeutics USD 211.07M 74.73M 2025-12
J&J USD 18.97B 2.38B 2025-12
Neurocrine Biosciences USD 577.6M 22M 2025-12
Pacira USD 193.68M 27.32M 2025-12
Pfizer USD 12.91B 79.89B 2025-12
RedHill Biopharma USD 5.51M 1.08M 2024-06
Supernus Pharmaceuticals USD 197.75M 54.54M 2025-12
Vanda Pharmaceuticals USD 466M 20.33M 2025-09